Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.
Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.